
Bristol Myers Squibb & Co. (NYSE:BMY), in collaboration with Johnson & Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS) event.
- BMY shares are retreating from recent levels. Review the technical setup here